公开(公告)号：WO2020243777A1

公开(公告)日：2020-12-10

申请号：PCT/AU2020/050562

申请日：2020-06-03

申请人： HAVAH THERAPEUTICS PTY LTD

发明人： BIRRELL, Stephen Nigel

IPC分类号： A61K31/568 ,  A61K31/5685 ,  A61K31/4196 ,  A61K47/12 ,  A61K9/00 ,  A61P5/26 ,  A61P43/00

摘要： The present disclosure is directed formulations, delivery systems and/or methods of use that have a novel a sustained release multi-phasic concentration pattern that may be used, among other things, for reducing mammographic breast density and/or breast stiffness in warm-blooded animals. For example, the formulation may comprise: the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor to a subject that provides a sustained release multi-phasic concentration pattern in the blood of the subject over time as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor and improves, amoung other things, breast tissue stabilization and/or increases of the levels of androgen receptor expression. The present disclosure is also directed to the use of an effective amount of an androgenic agent in combination with an effective amount of an aromatase inhibitor for the prophylaxis or treatment of autoimmune inflammatory mastitis (AIM) in a patient in 15 need thereof. Autoimmune inflammatory mastitis includes the conditions of idiopathic inflammatory macromastia, plasma cell mastitis, granulomatous mastitis.

公开(公告)号：WO2017066827A1

公开(公告)日：2017-04-27

申请号：PCT/AU2016/050973

申请日：2016-10-17

申请人： HAVAH THERAPEUTICS PTY LTD

发明人： BIRRELL, Stephen Nigel

IPC分类号： A61K31/568 ,  A61K31/585 ,  A61K31/4196 ,  A61K31/5685 ,  A61P43/00 ,  A61P35/00

CPC分类号： A61K31/568 ,  A61K9/0019 ,  A61K9/20 ,  A61K31/277 ,  A61K31/402 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/4745 ,  A61K31/565 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00

摘要： The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre- menopausal, a peri-menopausal or a post-memopausal patient, comprising the admimstration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reduing elasticity and/or decreasing mechano -transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.

摘要翻译： 本公开内容通常涉及用于治疗有需要的患者的乳房X线照片乳房密度和/或乳房硬度的方法和/或组合物，所述患者例如绝经前，绝经期或 包括施用有效量的雄激素剂和有效量的芳香酶抑制剂。 本公开还涉及用于减轻乳房疼痛的方法和/或组合物。 本公开还涉及用于降低乳房细胞基因组上的弹性和/或减少机械 - 转导的方法和/或组合物。 本公开还涉及用于稳定和/或增加乳房组织中雄激素受体表达水平的方法和/或组合物。